

PHARMACOGENOMIC INSIGHTS INTO PERSONALIZED DRUG THERAPY: INTEGRATING MOLECULAR GENETICS AND PRECISION MEDICINE FOR IMPROVED CLINICAL OUTCOMES

Swathi Ratnam Regidi^{1*}, Surabhi Johari², Sanskar Singh³, Navjot Kaur⁴, Fazil Ahmad⁵, Akkiraju Pavan Chand⁶

¹Associate Professor, Department of Pharmacology, MD Pharmacology, Dr NTR UHS,
Email Id: sweetyswathi12@gmail.com

²Professor, Department Of Biosciences, Computer Aided Drug Designing, Institute Of Management Studies Ghaziabad (University Courses Campus), Email id: surabhi.johari@imsuc.ac.in , Orcid Id: 0009-0009-9380-7121

³Research Scholar, Department of Pharmaceutics, BIU College of Pharmacy, Bareilly International University, Bareilly, Uttar Pradesh. Email id: sanskarhdi@gmail.com , Orcid Id: 0009-0004-1555-9429

⁴Research Scholar, Department of Pharmaceutics, BIU College of Pharmacy, Bareilly International University, Bareilly, Uttar Pradesh. Email id: kaurnavjot2636@gmail.com , Orcid Id: 0009-0009-0816-0459

⁵Department of Anesthesia Technology, College of Applied Medical Sciences in Jubail, Imam Abdulrahman Bin Faisal University, P.O. Box 4030, Jubail, Saudi Arabia. Email Id: fmahmad@jau.edu.sa ,Orcid Id: <https://orcid.org/0000-0002-0483-4702>

⁶Associate Professor, Department of Medical Biotechnology, School of Allied & Healthcare Sciences, Malla Reddy University, Hyderabad, India, Email Id: drakkiraju_pavanchand@mallareddyuniversity.ac.in, Orcid Id: 0000-0002-0170-4259

ABSTRACT:

Through an understanding of the role of inherited and acquired genetic variation in differences in drug metabolism, efficacy and toxicity, pharmacogenomics is changing the landscape of personalized drug therapy. In this review, the molecular and genetic basis of pharmacogenomic variability, clinically relevant biomarkers, enabling technologies, therapeutic applications, implementation pathways, and implications for clinical outcomes will be explored. Collectively, common variants, rare variants, copy-number variants, drug-target variation, and gene-environment interactions contribute to pharmacokinetic (PK) and pharmacodynamic (PD) variability. Advances in targeted genotyping, next-generation and long-read sequencing, multi-omics, pharmacomicrobiomics, and artificial intelligence are expanding the ability to identify actionable biomarkers and predict individualized drug responses. The clinical use of genotype-based approaches is becoming increasingly apparent in cardiovascular medicine, oncology, psychiatry, HIV treatment, and transplantation, where genotype-based approaches can assist in drug selection, dose optimization, reduction of drug toxicity, and optimizing treatment response. Factors that continue to limit the translation to routine care include the availability of variable-strength evidence, cost of implementation, clinician preparedness, electronic health record integration, and population diversity. Further advances will require robust multi-gene models that have been validated, clinical decision support systems that can be interoperable across institutions, a more diverse population and the incorporation of genomic data with multi-omics and clinical data. Pharmacogenomics is thus an important avenue for improved precision prescribing, which is safer, more effective and more personalized.

KEYWORDS: Pharmacogenomics, Personalized medicine, Precision medicine, Genotype-guided therapy, Drug response

INTRODUCTION

Although drug therapy is the cornerstone of contemporary clinical care, there is considerable heterogeneity of response to a given drug in the population. Drug development has traditionally relied on basic biological research to identify therapeutic targets and translate mechanistic discoveries into clinical interventions; however, interindividual variability can complicate the transition from drug efficacy under controlled conditions to therapeutic effectiveness in heterogeneous patient populations (Mohs & Greig, 2017). The variation in response to treatment may be due to demographic, physiological, environmental, disease-related and genetic factors. The need to consider greater diversity of clinical trials has, as a consequence, gained importance for understanding factors that impact drug exposure, efficacy and safety, within patients of different populations (Gross et al., 2022). For treatments with a narrow therapeutic window such as conventional chemotherapy, differences in systemic exposure and sensitivity to toxicity can significantly impact treatment, as shown by this example (Sprangers et al., 2019).

One part of this interindividual variability can be understood at a molecular level through pharmacogenomics, which involves analyzing the variation in the genome of people and how it affects drug disposition and response. Incorporating it into personalized medicine can provide an avenue to go beyond one-size-fits-all prescribing to customized treatments based on the biology of each patient (Cecchin & Stocco, 2020). Pharmacokinetic and pharmacodynamic alterations due to genetic variants in drug-metabolizing enzymes, transporters, receptors, immune-response pathways, and therapeutic targets can alter the optimal choice of a drug, its dose requirements,

the effectiveness of the drug treatment, and risk for adverse reactions. Pharmacogenomics has become an important aspect of precision medicine, with varying degrees of clinical implementation across drugs, specialties, and healthcare systems (Pirmohamed, 2023).

The translation of molecular findings to clinical decisions relies on an accurate understanding of the genotype–phenotype relationships and careful analysis of clinically actionable data. The evaluation of gene–drug associations and the need to make personalized therapeutic recommendations based on pharmacogenomic knowledge have therefore become a necessity and require the use of evidence-based frameworks to assess if the knowledge is sufficiently robust to support such recommendations (Whirl-Carrillo et al., 2021). In this way, curated resources like PharmGKB have helped facilitate this process by structuring information on genomic variation, drug response, clinical annotations, and pharmacogenomic guidelines in an accessible knowledge infrastructure (Barbarino et al., 2018). The clinical relevance is particularly evident in oncology, where genetic polymorphisms associated with drug metabolism and elimination can impact the pharmacokinetics of anticancer drugs, and thus influence the systemic exposure, toxicity and therapeutic benefit (Bertholee et al., 2017). Recent advances in computational methods are also beginning to expand the field to individual gene–drug interactions. The potential of AI to connect intricate molecular and clinical data in drug discovery, formulation, delivery, and therapeutic optimization paves the way for a more data-informed approach to personalized treatment. AI’s ability to bring together complex molecular and clinical information in drug discovery, formulation, delivery, and therapeutic optimization opens the door to a more data-driven personalization of treatment (Serrano et al., 2024). Despite these advances, there is a significant difference between the discovery of pharmacogenomics and the regular use in the clinical setting. Variability in evidence strength for gene–drug pairs, insufficient representation of diverse populations, and issues with variant interpretation, clinical decision support, standardization, accessibility, and benefit at the outcome level remain. Thus, the field needs an integrated assessment of molecular genetics with clinically actionable pharmacogenomic evidence and current precision medicine strategies. The purpose of this review is to discuss the molecular and genetic bases of variable drug responses, the clinical relevance of pharmacogenomic biomarkers and technologies, their role in drug selection and dosing, and to critically review their potential for enhancing the therapeutic efficacy, safety, and clinical outcomes of drug use, highlighting existing challenges and prospects for precision pharmacotherapy.

2. Molecular and Genetic Foundations of Pharmacogenomics

The extent of interindividual differences in drug response can be attributed, to a large extent, to intergenetic variations across the genome of genes related to drug metabolism, transport, regulation and molecular targeting. Polymorphisms are known to cause a significant amount of pharmacogenomic variation, but rare functional polymorphisms can cause dramatic changes in protein function, drug exposure, therapeutic efficacy, and drug toxicity. Rare variants in cellular transporters, metabolic enzymes and nuclear receptors might thus account for clinically relevant response phenomena that are currently not captured by standard pharmacogenomic tests (Kozyra et al., 2017). The use of these variants in pharmacogenetic prediction models may lead to a better understanding of genotype–phenotype relationships, but they must also be functionally characterize and validated for clinical use (Ingelman-Sundberg et al., 2018). In addition, structural genomic variation contributes to the genetic variation in response to drugs. Moreover, the genetic architecture of pharmacological response is further enriched by SV. Copy-number variations may lead to gene deletion, duplication or multiple copies, which can affect the expression and the activity of pharmacogenes. Novel copy number variations detected in pharmacologically relevant genes show that structural variation can make a significant contribution to inter-individual differences in pharmacokinetics and may not be detected by methods mainly targeting single nucleotide variants (SNVs) (Santos et al., 2018). Pharmacokinetic variability is the result of inter-individual variation in the processes of drug absorption, distribution, metabolism and elimination, all of which affect the systemic exposure and concentration of an active compound at the site of its action. Absorption and distribution are influenced by the drug's physicochemical properties, gastrointestinal physiology, membrane permeability, blood flow, and protein binding, as well as the patient's physiology (Chillistone & Hardman, 2017). In addition, to the substantial variation in metabolic capacity caused by genetic polymorphisms in the major cytochrome P450 enzymes. Polymorphisms in the genes of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 may produce different metabolic phenotypes that have the potential to alter drug clearance, dosage, therapeutic response, and response to concentration-dependent drug toxicity (Ganoci et al., 2017).

Genotype is not the only factor that determines biological processes of drug disposition. Pharmacometabolomics is a way to measure dynamic metabolic phenotypes that reflect the interplay between genetic background, physiological state, environmental factors and disease processes. Analysis of metabolomic profile in combination with pharmacokinetic and pharmacodynamic measurements could, therefore, enhance the characterization of individual responses to drugs and provide a wider biological context for optimal personalized drug therapy (Kantae et al., 2017). Another important aspect of pharmacogenomics is pharmacodynamic variability, which occurs when changes in the genetic material of the cell can alter drug targets, receptors, enzymes, ion channels, and downstream signal transduction pathways. Small mutations of drug-target genes can occur in humans, which would affect the structure or function of the protein and impact drug sensitivity, although systemic exposure would be similar. Analyzing the functional differences in therapeutic targets can reveal patients with distinct response patterns and enhance the precision of treatment using genetic information for drug selection (Zhou et al., 2021).

Genetically determined phenotypes can also be affected by drug–drug–gene interactions that occur upon exposure to medication. Medicines that are co-administered and that inhibit or induce a genetically variable enzyme may lead to unexpected changes in the functional phenotype predicted by the genotype, resulting in alterations in the level of the drug or effect of the drug. These interactions are especially relevant in the context of adverse drug reactions, and show that a full medication history must be taken, and not just the genetic information alone, into consideration when interpreting the pharmacogenomic information (Malki & Pearson, 2020). In addition to inherited genetic variation, environmental factors also affect molecular pathways and their phenotypic expression. The regulation of genes and biological processes can be influenced by diet, lifestyle, pollutants, infections and other exposures and contribute to inter-individual variability through the gene–environment interaction. Considering these dynamic interactions can help enhance the predictive power of pharmacogenomics as it integrates relatively stable genomic data with environmental and physiological factors that vary across the lifespan of the individual (Virolainen et al., 2023).

Thus, the molecular basis of pharmacogenomics is broader than just single genetic polymorphisms, and includes rare genetic variants, structural variation, metabolic phenotypes, drug-target variation and environmental interactions. Combining these determinants provides a more solid biological foundation in predicting drug efficacy, optimizing drug exposure, and decreasing toxicity in personalized pharmacotherapeutics. The main genetic variations involved in drug disposition and drug response are listed in Table 1.

Table 1. Major Genetic Factors Influencing Drug Response

Genetic factor	Main mechanism	Effect on therapy	Clinical relevance	Source
SNPs	Alter protein function	Variable response	Dose or drug adjustment	Kozyra et al., 2017
Rare variants	Modify enzyme activity	Unusual response	Improved phenotype prediction	Ingelman-Sundberg et al., 2018
Copy-number variation	Changes gene copies	Altered metabolism	Exposure variability	Santos et al., 2018
CYP polymorphisms	Change drug metabolism	Altered clearance	Dose optimization	Ganoci et al., 2017
Drug-target variants	Modify target function	Altered sensitivity	Treatment selection	Zhou et al., 2021
Gene–drug interactions	Modify predicted phenotype	Toxicity or failure	Medication review	Malki & Pearson, 2020

3. Pharmacogenomic Biomarkers and Enabling Technologies

Pharmacogenomic biomarkers are measurable genomic indicators that can be used to predict the variation in drug effectiveness, optimal dosage, metabolism and side effects. Their clinical utility relies on the degree of association between the gene and the drug, the functional impact of the gene variant, and the evidence of association between the use of the genetic information and better therapeutic outcomes. Advances in biomarker discovery have broadened the scope of actionable genetic information available for personalized treatment, yet the process of biomarker validation is an arduous one that requires careful consideration and diligence before biomarkers will be routinely used in clinical practice (Lauschke et al., 2017). Cytochrome P450 enzymes continue to be among the most established pharmacogenomic biomarkers as they are known to affect the metabolism of a multitude of widely used drugs. Variation in CYP genes may have a significant functional consequence, potentially leading to a wide range of enzyme activity and thereby to different exposures to the systemic circulation of drugs. The variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A5 are relevant for genotype-guided prescribing due to the ability to categorize them into clinically relevant metabolic phenotypes (Tornio & Backman, 2018). Findings from patients receiving multiple drugs also suggest that these pharmacogenomic phenotypes may be of more general applicability in more complex prescribing settings in which there is greater variability in exposure and drug-related problems, arising from polypharmacy (Krulikas et al., 2024). A new class of immune-related biomarkers takes pharmacogenomics beyond metabolism. The severity of cutaneous adverse drug reactions (AADRs), such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), is significantly associated with certain human leukocyte antigen (HLA) variants for certain drugs. A clinically important example of the use of pharmacogenomics to prevent potentially life-threatening toxicity is pre-treatment identification of high-risk HLA alleles, which is not just to optimize drug concentrations or therapeutic efficacy (Kloypan et al., 2021). Pharmacogenomic testing has been greatly amplified in size and detail through technological advances. There are several methods available, including targeted genotyping and allele-specific assays, microarray, next-generation sequencing, whole-exome sequencing and whole-genome sequencing. The choice of a platform should be based on the analytical coverage, turnaround time, cost, variant types, and clinical use. While there are advantages to broad sequencing technology, these also come with the challenges of interpretation and bioinformatic processing (van der Lee et al., 2020). Long-read sequencing can be used to further resolve structurally complex pharmacogenes, haplotypes, copy-number variation and regions that may be difficult to accurately characterize

with short-read sequencing. It has been increasingly applied to enhance the accuracy of allele assignment and the prediction of a patient's pharmacogenomic phenotype, but there are still some analytical challenges to overcome and the need to confirm the results in the clinic (Tafazoli et al., 2025). The pharmacogenomics paradigm is evolving from single-genomic markers to a system-level characterization of biological systems, through multi-omics technologies. The genomic information together with transcriptomic, proteomic, epigenomic and metabolomic data can be used to infer the dynamic molecular phenotypes that are influenced by genomic variation and can affect treatment response. Bioinformatic integration of these molecular layers can reveal regulatory networks and drug-response signatures that may not be identified from genomic data alone, supporting more comprehensive therapeutic stratification (Bachhav et al., 2025). Precision medicine is another approach that uses omics data to link molecular heterogeneity with disease characteristics and therapeutic response to gain more insight into the discovery of new biomarkers and patient classification (Hasanzad et al., 2022).

Another biological layer, the microbiome, is also able to influence pharmacological response. Drugs can be metabolized directly by gut microflora, alter host metabolic pathways and affect drug bioavailability, efficacy and toxicity. Thus, Pharmacomicrobiomics complements the host Pharmacogenomics, and could eventually prove to be useful in designing therapeutic strategies that integrate human genomics and microbiome information, where inter-individual microbial variation is a factor (Sharma et al., 2019). Identification of clinically relevant patterns in high-dimensional multi-omics and pharmacogenomic datasets has become integral to the use of artificial intelligence. Genomic variations can be combined with molecular profiles, clinical features and responses to treatment in machine-learning approaches to detect complex associations and model a patient's drug response. AI-powered multi-omics analysis could then aid in prioritizing biomarkers and in predicting individual treatments, as long as models are validated against an external cohort, explainable, and from a representative population (Zack et al., 2025).

The journey towards developing pharmaceutical biomarkers is moving from single gene–drug associations to multidimensional molecular profiling, with advanced sequencing, multi-omics, microbiome analysis and artificial intelligence. The impact of these technologies will be determined by the ability to translate increasingly complex biological data into credible, meaningful, and clinically useful recommendations, which help guide treatment decisions. To date, the most important pharmacogenomic biomarkers and technologies that are currently used to aid precision drug therapy are shown in Table 2.

Table 2. Key Pharmacogenomic Biomarkers and Technologies

Biomarker/technology	Primary role	Main advantage	Key limitation	Source
CYP2D6	Drug metabolism	Widely actionable	Complex allele structure	Tornio & Backman, 2018
CYP2C19	Drug metabolism	Guides several therapies	Phenoconversion	Krulik et al., 2024
HLA variants	Toxicity prediction	Prevents severe reactions	Population variability	Kloypan et al., 2021
Targeted genotyping	Known variant detection	Fast and practical	Limited variant coverage	van der Lee et al., 2020
Long-read sequencing	Complex variant detection	Resolves haplotypes/CNVs	Cost and standardization	Tafazoli et al., 2025
Multi-omics/AI	Integrated prediction	Captures complex biology	Validation required	Zack et al., 2025

4. Clinical Applications in Personalized Drug Therapy

Pharmacogenomics is an emerging field that is impacting cardiovascular pharmacotherapy by directing treatment choice based on the genetic characteristics of drug metabolism and response. One of the more significant applications is antiplatelet therapy, specifically when genetic variation impacts how a drug is metabolized into its therapeutic form and its response. With the incorporation of pharmacogenomic data alongside clinical risk factors, personalized antiplatelet regimens may help to better identify patient groups who may benefit from alternative agents or adjusted treatment, potentially offering enhanced ischemic protection while reducing bleeding risks (Oliva et al., 2023). There is also evidence of precision approaches in the field of anticoagulation, such as using patient characteristics to inform personalized choices and management of thromboprophylaxis instead of standardizing treatment for a diverse population (Nasiri et al., 2025). In oncology, there is one of the best-developed settings where personalized drug therapy can be provided since both tumor-specific molecular alterations and germline variation can impact drug selection, effectiveness and safety. Molecular profiling helps guide treatment decisions to more actionable biological features of malignancies, and ultimately, to more personalized cancer treatment (Krzyszczuk et al., 2018). Also, there is significant relevance to pharmacogenetic testing in the area of reducing the toxicity of treatment. Genetic variations that influence the metabolism or disposition of anticancer drugs can help identify patients who are at higher risk for severe adverse reactions, and can guide dose modification or alternative treatment selection prior to clinically significant toxicity occurring (Mhandire & Goey, 2022).

Neurology and psychiatry have more complex applications, with responses to treatments often resulting from interactions between genetic, molecular, environmental and clinical factors. In these fields, frameworks for precision medicine are increasingly combining biomarkers, neuroimaging, omics information and patient-level features to enhance disease stratification and therapeutic choices (Hampel et al., 2023). When it comes to psychiatric pharmacotherapy, there is significant variation in the response to medication and the side effects encountered. Biological models that predict the individual's response may provide additional information to pharmacogenomic information and may be used to narrow the range of therapeutic options for patients who are more likely to respond to a particular regimen, but solid clinical validation is needed before these are widely applied (Stern et al., 2018).

In addition, pharmacotherapy can be tailored to an individual's disease state in infectious diseases. The treatment of HIV should be effective over the long-term, with minimum toxicity, resistance, and treatment burden. Personalized approaches, based on molecular information and clinical parameters, to optimise therapeutic regimens throughout infection are supported by biological pathway and therapeutic response variability observed between individuals (Kumbale & Voit, 2021). Another clinically relevant area of transplantation is due to the narrow therapeutic indices of certain immunosuppressive agents and the high interindividual pharmacokinetic variability. Variability in treatment requirements or under- or overexposure to immunosuppressants can be caused by genetic differences in enzymes and transporters involved in disposition. The use of pharmacogenetic information in therapeutic drug management (TDM) may thus help to provide more personalized dosage and, combined with routine concentration monitoring, be helpful when optimal exposure is needed to ensure graft protection (Salvadori & Tsalouchos, 2020).

The potential of pharmacogenomics for clinical use is most obvious when genetics inform a therapy choice, dose optimization, or prevention of drug toxicity. These examples of cardiovascular medicine, oncology, neuropsychiatry, infectious diseases and transplantation show the shift to patient-centered pharmacotherapy, but levels of evidence and clinical application are not uniform across therapeutic areas. Table 3 outlines some of the most representative clinical applications of pharmacogenomics for each of the major therapeutic areas.

Table 3. Clinical Applications of Pharmacogenomics Across Therapeutic Areas

Clinical area	Pharmacogenomic focus	Therapeutic purpose	Expected benefit	Source
Cardiovascular care	Antiplatelet response	Drug selection	Lower ischemic/bleeding risk	Oliva et al., 2023
Anticoagulation	Patient-specific response	Individualized therapy	Safer thromboprophylaxis	Nasiri et al., 2025
Oncology	Drug metabolism/toxicity	Dose and drug selection	Reduced toxicity	Mhandire & Goey, 2022
Psychiatry	Treatment response	Therapy selection	Improved response	Stern et al., 2018
HIV/AIDS	Molecular variability	Regimen optimization	Better treatment control	Kumbale & Voit, 2021
Transplantation	Immunosuppressant metabolism	Dose optimization	Improved drug exposure	Salvadori & Tsalouchos, 2020

5. Translation of Pharmacogenomics into Clinical Practice

Identification of statistically significant gene–drug association is not sufficient to translate pharmacogenomics to routine care. Before a biomarker can assist decision makers in prescribing therapy, it will need to exhibit analytical validity, clinical validity, and clinical utility. Thus, discovery pipelines must also include strong replication, functional interpretation, and prospective evaluation, and genomic discovery has to be translated into actionable recommendations, instead of being an observation of a research process. (Arbitrio et al., 2021) Clinical implementation also requires coordinated infrastructure that integrates pharmacogenomic testing, interpretation, and clinical recommendations directly into prescribing workflows. There is evidence from large-scale European projects that pre-emptive testing can be integrated into healthcare systems by using standardised genotyping, harmonized interpretation, clinical decision support, and a cross-institutional implementation framework. In particular, pharmacogenomic findings can be applied across multiple encounters in which a patient is prescribed a medication and may continue to be relevant for a patient's lifetime (van der Wouden et al., 2017). However, the interpretation of genetic information at the point of care needs to be done in the context of the clinical situation. The choice of drug and dosage should be based on genotype-driven phenotype, concomitant drugs, organ function, age, disease status and any other factors which could affect drug response. Clear laboratory reporting, suitable test selection and access to evidence-based recommendations that can easily be integrated into clinical decisions for treatment are also necessary for practical implementation (Nicholson et al., 2021).

There are still some obstacles to adoption. Lack of clinician familiarity, inconsistent reimbursement, access to testing, and limited integration with electronic health records, as well as who is responsible for interpretation, can lower clinician uptake. There may also be inconsistencies between healthcare systems due to varying levels of fit

for the guidelines and the thresholds for the evidence. To overcome these barriers, standardized clinical pathways, professional education, interoperable digital systems and more robust integration of pharmacogenomic information into daily clinical activities are needed (Klein et al., 2017). Strong clinical evidence is another factor to consider when determining implementation. Some gene–drug combinations are well supported by data and clear prescribing recommendations, while others have a limited or conflicting amount of data on the question of whether improvement of outcome is achieved. Evidence, therefore, should be assessed for the utility of introducing PGx testing selectively for changes in treatment decisions, rather than assuming that all genetic information available has an equal clinical benefit (Hippman & Nislow, 2019).

Achieving successful translation of pharmacogenomics requires linking validated biomarkers with actionable guidelines, electronic decision support, clinician experience, and healthcare system preparedness. The field will best be promoted by ways in which genomic information is integrated into the routine practice of prescribing, evidence-based, accessible and clinically actionable. The use of pharmacogenomic biomarkers in personalized prescribing, as well as implementation requirements and barriers, is illustrated in the pathway from pharmacogenomic biomarker discovery to personalized prescribing (Figure 1).




Figure 1. Translation of Pharmacogenomics into Clinical Practice

6. Impact on Clinical Outcomes and Healthcare

Whether genetic information can provide a measurable benefit to the treatment of patients over traditional prescribing is the key to understanding the clinical utility of pharmacogenomics. Genotype-based therapy can detect clinically relevant gene–drug interactions and serve as a foundation for adjusting drug selection and/or dosage before treatment failure or toxicity. In psychiatric pharmacotherapy, randomized evidence suggests that adjusting treatment based on the genetic information of patients who have relevant gene–drug interactions could lead to better clinical outcomes, suggesting that there may be value in using pharmacogenomic information for prescribing in the right population (Thase et al., 2019). Variability in response and tolerability of antidepressants has been explored especially in dysthymia and depressive disorders, in which the variability of antidepressant response continues to be a clinical issue. The use of pharmacogenomic tests that include CYP2D6 and CYP2C19 polymorphisms may give information concerning inter-individual differences in the metabolism of antidepressants and possible treatment suitability. Pharmacogenomic-guided treatment has shown some promise in enhancing treatment outcomes in depression, according to a synthesis of evidence from RCTs, although the consistency and level of benefit have been influenced by the type of test, the study design, and the clinical population studied (Arnone et al., 2023). Another important outcome of the implementation of pharmacogenomics is medication safety. Combination drugs may impact the metabolism of the genetic findings, and so phenocconversion must be taken into account. Pharmacogenomic-informed medication review may assist in identifying drug–gene and drug–drug–gene interactions that could otherwise lead to suboptimal pain management, side effects, and/or a decreased quality of life. These examples highlight the importance of using genomic data alongside current clinical data and not just static genotype classifications only (Muhn et al., 2022).

The clinical utility of pharmacogenomic testing must be proven with strong evidence that the testing results help patients or providers, and that the benefits are measurable. Are the correct clinical trial designs required to assess the impact of testing on prescribing practices and the impact of the changes on efficacy and/or fewer adverse events or other clinically relevant measures? Trial methodology is thus a key part of understanding how to separate out clinically useful pharmacogenomic interventions from potential associations which are biologically plausible but not yet compelling enough to be used as a routine therapy (Drozda & Pacanowski, 2017). The cost and availability of pharmacogenomic services are also covered by the impact on healthcare. Implementation costs involve testing, laboratory facilities, clinical interpretation, workforce development, and implementation of decision-support systems; potential benefits include avoiding ineffective therapy, avoiding adverse drug reactions, and increasing therapeutic efficiency. In resource-limited systems, where costs are a major constraint, along with population-specific evidence, infrastructure, and competing healthcare priorities, pharmacogenomic strategies must be considered in relation to sustainability for potential translation into clinical care (Alimohamed et al., 2025).

Pharmacogenomics provides a mechanism for enhancing healthcare when genetic data results in clinically meaningful variations in treatment choice, dosage, safety or therapeutic response. The generalizability will rely on the degree of outcome evidence, on a growing understanding of factors like phenoconversion, on careful and comprehensive clinical assessment, and on the economic viability of genotype-driven treatment in the context of a wide range of healthcare systems. Pharmacogenomic-guided therapy has a number of significant effects on treatment effectiveness, medication safety, patient outcomes, and healthcare value, which are summarized in Figure 2.




Figure 2. Impact of Pharmacogenomic-Guided Therapy on Clinical and Healthcare Outcomes

7. Challenges and Future Perspectives

There remain scientific and technical barriers as well as problems within the healthcare system to the translation of pharmacogenomics within clinical practice. The interpretation of genetic variants is challenging, as the level of evidence, the classification of the allele, the conversion of the genotype to the phenotype and the clinical actionability of the results differ greatly between different gene–drug pairs. Rigid expectations of the same evidence for all pharmacogenomic associations can also be a barrier to implementation of clinically useful information, however, and a balance must be struck between the rigor of the evidence and implementation (Krebs & Milani, 2019). The testing cost, the uncertainty of reimbursement, lack of clinician experience, laboratory requirements, population-specific differences, and inconsistent availability of standardized prescribing guidelines are other factors that limit therapeutic implementation (Lam & Scott, 2018). Experience with multigene pharmacogenetic programs shows that there are also other issues to consider, such as integration with the EHR, clinical decision support alerts, provider engagement, result communication, and the use of lifelong genomic information in repeated prescribing encounters (Cicali et al., 2019). As more genomic and clinical data becomes

available, additional concerns about interoperability, complexity of analyses, data quality, privacy and reproducibility arise. The constraints of these are especially relevant in the context of pharmacogenomics becoming integrated into precision medicine and increasing dependence on the use of large, heterogeneous datasets for therapeutic prediction (Primorac et al., 2020).

Pharmacogenomics will need to evolve from a relatively simple modeling approach of gene–drug associations to a modeling approach that represents the biological complexity of treatment response. The incorporation of genomic variants into transcriptomic, proteomic, metabolomic, clinical, environmental, and treatment history data may allow us to get a more comprehensive picture of individual therapeutic phenotypes. Polygenetic effects, molecular pathways, disease heterogeneity and treatment context can be evaluated concurrently at the system-level through the use of computational approaches and advanced predictive modeling, which will aid in the identification of the most appropriate drug and dose for an individual patient (Kalamara et al., 2018). These models will need to be validated in prospective studies, have meaningful clinical algorithms, population data that's representative, digital infrastructure that's interoperable and decision support systems that can provide actionable information at the time of prescription if they're going to be widely implemented. Eventually, the information gathered through pre-emptive multigene profiling could be a repeatable part of patients' lifelong health records to be used for multiple therapeutic decisions over the course of a patient's life. The future of the field is thus focused on translating more complicated molecular information into accessible, reliable and equitable precision-prescribing strategies.

Central is not just the identification of pharmacogenomic associations but turning these associations into clinically interpretable and actionable, scalable tools. Advances will come on the heels of incorporating validated genomic evidence along with multidimensional patient information and strong digital systems to ensure safer and more accurate pharmacotherapy for each patient. Figure 3 provides an overview of the key challenges for clinical pharmacogenomics implementation and the new roadmap to precision and equitable care.




Figure 3. Challenges and Future Directions in Clinical Pharmacogenomics

8. CONCLUSION

The possibilities of personalized drug therapy are increasingly redefined by pharmacogenomics, which is concerned with the connection of molecular genetic variation to clinically relevant variation in drug metabolism, efficacy and toxicity. The assembled evidence indicates that individual responses to treatment is the result of a combination of common and rare variants, copy number changes, pharmacokinetic genes, variation in drug targets, and gene–environment interactions. The development of pharmacogenomic biomarkers, sequencing technologies, integration of multi-omics and the use of artificial intelligence is increasing the ability to detect actionable variation and making more precise treatment decisions. From cardiovascular medicine to oncology, psychiatry to infectious disease and transplantation, the increasing importance of genotype-guided prescribing in optimizing doses, reducing toxicity and treating individuals is now reflected in clinical applications. The move from research to clinical practice is, however, still reliant on reliable and validated markers, electronic health record (EHR) interoperability, physician and provider uptake, and support of patient-centered benefit. Going forward, studies will need to include more representative populations, more robust prospective research validation, scalable decision-supporting infrastructure, and the integration of genomic information and multi-omics, clinical, and environmental information. Thus, the field of pharmacogenomics is poised to play a vital role in precision medicine if science can be translated into easy-to-use, accurate, and clinically relevant prescribing guidelines.

REFERENCES

1. Alimohamed, M. Z., Obeng, G. D., Csanadi, M., Masimirembwa, C., & Dandara, C. (2025). Implementing health economics for pharmacogenomics research translation in Africa. *Communications medicine*, 5(1), 241.
2. Arbitrio, M., Scionti, F., Di Martino, M. T., Caracciolo, D., Pensabene, L., Tassone, P., & Tagliaferri, P. (2021). Pharmacogenomics biomarker discovery and validation for translation in clinical practice. *Clinical and Translational Science*, 14(1), 113-119.

3. Arnone, D., Omar, O., Arora, T., Östlundh, L., Ramaraj, R., Javaid, S., ... & Stip, E. (2023). Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials. *Neuroscience & Biobehavioral Reviews*, 144, 104965.
4. Bachhav, G., Avhad, S., Bhalerao, J., Pache, M., Bhamare, A., & Ahirrao, S. (2025). Mapping Drug Responses Through Multi-Omics: A New Era of Bioinformatics in Precision Medicine. *International Journal of Scientific Research and Technology*, 2(8), 319-335.
5. Barbarino, J. M., Whirl-Carrillo, M., Altman, R. B., & Klein, T. E. (2018). PharmGKB: a worldwide resource for pharmacogenomic information. *Wiley Interdisciplinary Reviews: Systems Biology and Medicine*, 10(4), e1417.
6. Bertholee, D., Maring, J. G., & van Kuilenburg, A. B. (2017). Genotypes affecting the pharmacokinetics of anticancer drugs. *Clinical pharmacokinetics*, 56(4), 317-337.
7. Cecchin, E., & Stocco, G. (2020). Pharmacogenomics and personalized medicine. *Genes*, 11(6), 679.
8. Chillistone, S., & Hardman, J. G. (2017). Factors affecting drug absorption and distribution. *Anaesthesia & Intensive Care Medicine*, 18(7), 335-339.
9. Cicali, E. J., Weitzel, K. W., Elsey, A. R., Orlando, F. A., Vinson, M., Mosley, S., ... & Johnson, J. A. (2019). Challenges and lessons learned from clinical pharmacogenetic implementation of multiple gene-drug pairs across ambulatory care settings. *Genetics in Medicine*, 21(10), 2264-2274.
10. Drozda, K., & Pacanowski, M. A. (2017). Clinical trial designs to support clinical utility of pharmacogenomic testing. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 37(9), 1000-1004.
11. Ganoci, L., Božina, T., Mirošević Skvrce, N., Lovrić, M., Mas, P., & Božina, N. (2017). Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. *Drug metabolism and personalized therapy*, 32(1), 11-21.
12. Gross, A. S., Harry, A. C., Clifton, C. S., & Della Pasqua, O. (2022). Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response. *British Journal of Clinical Pharmacology*, 88(6), 2700-2717.
13. Hampel, H., Gao, P., Cummings, J., Toschi, N., Thompson, P. M., Hu, Y., ... & Vergallo, A. (2023). The foundation and architecture of precision medicine in neurology and psychiatry. *Trends in Neurosciences*, 46(3), 176-198.
14. Hasanazad, M., Sarhangi, N., Ehsani Chimeh, S., Ayati, N., Afzali, M., Khatami, F., ... & Aghaei Meybodi, H. R. (2022). Precision medicine journey through omics approach. *Journal of Diabetes & Metabolic Disorders*, 21(1), 881-888.
15. Hippman, C., & Nislow, C. (2019). Pharmacogenomic testing: clinical evidence and implementation challenges. *Journal of personalized medicine*, 9(3), 40.
16. Ingelman-Sundberg, M., Mkrtchian, S., Zhou, Y., & Lauschke, V. M. (2018). Integrating rare genetic variants into pharmacogenetic drug response predictions. *Human genomics*, 12(1), 26.
17. Kalamara, A., Tobalina, L., & Saez-Rodriguez, J. (2018). How to find the right drug for each patient? Advances and challenges in pharmacogenomics. *Current opinion in systems biology*, 10, 53-62.
18. Kantae, V., Krekels, E. H., Esdonk, M. J. V., Lindenburg, P., Harms, A. C., Knibbe, C. A., ... & Hankemeier, T. (2017). Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. *Metabolomics*, 13(1), 9.
19. Klein, M. E., Parvez, M. M., & Shin, J. G. (2017). Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. *Journal of pharmaceutical sciences*, 106(9), 2368-2379.
20. Kloypan, C., Koomdee, N., Satapornpong, P., Tempark, T., Biswas, M., & Sukasem, C. (2021). A comprehensive review of HLA and severe cutaneous adverse drug reactions: implication for clinical pharmacogenomics and precision medicine. *Pharmaceuticals*, 14(11), 1077.
21. Kozyra, M., Ingelman-Sundberg, M., & Lauschke, V. M. (2017). Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response. *Genetics in Medicine*, 19(1), 20-29.
22. Krebs, K., & Milani, L. (2019). Translating pharmacogenomics into clinical decisions: do not let the perfect be the enemy of the good. *Human genomics*, 13(1), 39.
23. Krulikas, L., Bates, J., Chanfreau, C., Coleman, H., Dalton, S., & Voora, D. (2024). Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans. *Clinical Pharmacology & Therapeutics*, 116(2), 390-396.
24. Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., ... & Yarmush, M. L. (2018). The growing role of precision and personalized medicine for cancer treatment. *Technology*, 6(03n04), 79-100.
25. Kumbale, C. M., & Voit, E. O. (2021). Toward personalized medicine for HIV/AIDS. *Journal of AIDS and HIV Treatment*, 3(2), 37.
26. Lam, Y. W. F., & Scott, S. R. (Eds.). (2018). *Pharmacogenomics: challenges and opportunities in therapeutic implementation*.
27. Lauschke, V. M., Milani, L., & Ingelman-Sundberg, M. (2017). Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. *The AAPS journal*, 20(1), 4.

28. Malki, M. A., & Pearson, E. R. (2020). Drug–drug–gene interactions and adverse drug reactions. *The pharmacogenomics journal*, 20(3), 355-366.
29. Mhandire, D. Z., & Goey, A. K. (2022). The value of pharmacogenetics to reduce drug-related toxicity in cancer patients. *Molecular diagnosis & therapy*, 26(2), 137-151.
30. Mohs, R. C., & Greig, N. H. (2017). Drug discovery and development: Role of basic biological research. *Alzheimer's & Dementia: Translational Research & Clinical Interventions*, 3(4), 651-657.
31. Muhn, S., Amin, N. S., Bardolia, C., Del Toro-Pagán, N., Pizzolato, K., Thacker, D., ... & Michaud, V. (2022). Pharmacogenomics and drug-induced phenocopy informed medication safety review in the management of pain control and quality of life: a case report. *Journal of Personalized Medicine*, 12(6), 974.
32. Nasiri, A., Alshammari, M., Alqahtani, R., Alshaer, O., Alsolamy, E., Alghethber, H., & Alkharras, R. (2025). Next-generation anticoagulants: precision strategies for patient-centered thromboprophylaxis. *Journal of Personalized Medicine*, 15(10), 490.
33. Nicholson, W. T., Formea, C. M., Matey, E. T., Wright, J. A., Giri, J., & Moyer, A. M. (2021, January). Considerations when applying pharmacogenomics to your practice. In *Mayo Clinic Proceedings* (Vol. 96, No. 1, pp. 218-230). Elsevier.
34. Oliva, A., Cao, D., Spirito, A., Nicolas, J., Pileggi, B., Kamaleldin, K., ... & Mehran, R. (2023). Personalized approaches to antiplatelet treatment for cardiovascular diseases: an umbrella review. *Pharmacogenomics and personalized medicine*, 973-990.
35. Pirmohamed, M. (2023). Pharmacogenomics: current status and future perspectives. *Nature Reviews Genetics*, 24(6), 350-362.
36. Primorac, D., Bach-Rojecky, L., Vađunec, D., Juginović, A., Žunić, K., Matišić, V., ... & Donaldson, M. (2020). Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data. *Pharmacogenomics*, 21(2), 141-156.
37. Salvadori, M., & Tsalouchos, A. (2020). Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy. *World Journal of Transplantation*, 10(5), 90.
38. Santos, M., Niemi, M., Hiratsuka, M., Kumondai, M., Ingelman-Sundberg, M., Lauschke, V. M., & Rodriguez-Antona, C. (2018). Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics. *Genetics in Medicine*, 20(6), 622-629.
39. Serrano, D. R., Luciano, F. C., Anaya, B. J., Ongoren, B., Kara, A., Molina, G., ... & Lalatsa, A. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: revolutionizing personalized medicine. *Pharmaceutics*, 16(10), 1328.
40. Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019). Pharmacomicrobiomics: the holy grail to variability in drug response?. *Clinical Pharmacology & Therapeutics*, 106(2), 317-328.
41. Sprangers, B., Cosmai, L., & Porta, C. (2019). 16 Conventional Chemotherapy. *Onco-Nephrology E-Book*, 128.
42. Stern, S., Linker, S., Vadodaria, K. C., Marchetto, M. C., & Gage, F. H. (2018). Prediction of response to drug therapy in psychiatric disorders. *Open biology*, 8(5), 180031.
43. Tafazoli, A., Hemmati, M., Rafigh, M., Alimardani, M., Khaghani, F., Korostyński, M., & Karnes, J. H. (2025). Leveraging long-read sequencing technologies for pharmacogenomic testing: applications, analytical strategies, challenges, and future perspectives. *Frontiers in genetics*, 16, 1435416.
44. Thase, M. E., Parikh, S. V., Rothschild, A. J., Dunlop, B. W., DeBattista, C., Conway, C. R., ... & Greden, J. F. (2019). Impact of pharmacogenomics on clinical outcomes for patients taking medications with gene-drug interactions in a randomized controlled trial. *J Clin Psychiatry*, 80(6), 19m12910.
45. Tornio, A., & Backman, J. T. (2018). Cytochrome P450 in pharmacogenetics: an update. *Adv Pharmacol*, 83, 3-32.
46. van der Lee, M., Kriek, M., Guchelaar, H. J., & Swen, J. J. (2020). Technologies for pharmacogenomics: a review. *Genes*, 11(12), 1456.
47. van der Wouden, C. H., Cambon-Thomsen, A., Cecchin, E., Cheung, K. C., Dávila-Fajardo, C. L., Deneer, V. A., ... & Ubiquitous Pharmacogenomics Consortium. (2017). Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. *Clinical Pharmacology & Therapeutics*, 101(3), 341-358.
48. Virolainen, S. J., VonHandorf, A., Viel, K. C., Weirauch, M. T., & Kottyan, L. C. (2023). Gene–environment interactions and their impact on human health. *Genes & Immunity*, 24(1), 1-11.
49. Whirl-Carrillo, M., Huddart, R., Gong, L., Sangkuhl, K., Thorn, C. F., Whaley, R., & Klein, T. E. (2021). An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. *Clinical Pharmacology & Therapeutics*, 110(3), 563-572.
50. Zack, M., Stupichev, D. N., Moore, A. J., Slobodchikov, I. D., Sokolov, D. G., Trifonov, I. F., & Gobbs, A. (2025). Artificial intelligence and multi-omics in pharmacogenomics: a new era of precision medicine. *Mayo Clinic Proceedings: Digital Health*, 3(3), 100246.
51. Zhou, Y., Arribas, G. H., Turku, A., Jürgenson, T., Mkrtchian, S., Krebs, K., ... & Lauschke, V. M. (2021). Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. *Science Advances*, 7(36), eabi6856.